Free Trial

Navidea Biopharmaceuticals (NAVB) Competitors

Navidea Biopharmaceuticals logo
$0.0002 0.00 (0.00%)
As of 07/3/2025

NAVB vs. VRPX, KRBP, MYMD, TCBP, CAPS, VINC, BON, UPC, SMFL, and HSTO

Should you be buying Navidea Biopharmaceuticals stock or one of its competitors? The main competitors of Navidea Biopharmaceuticals include Virpax Pharmaceuticals (VRPX), Kiromic BioPharma (KRBP), MyMD Pharmaceuticals (MYMD), TC Biopharm (TCBP), Capstone Therapeutics (CAPS), Vincerx Pharma (VINC), Bon Natural Life (BON), Universe Pharmaceuticals (UPC), Smart for Life (SMFL), and Histogen (HSTO). These companies are all part of the "pharmaceutical products" industry.

Navidea Biopharmaceuticals vs. Its Competitors

Navidea Biopharmaceuticals (NYSE:NAVB) and Virpax Pharmaceuticals (NASDAQ:VRPX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.

0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. Comparatively, 32.2% of Virpax Pharmaceuticals shares are owned by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are owned by insiders. Comparatively, 3.7% of Virpax Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Navidea Biopharmaceuticals' return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Navidea BiopharmaceuticalsN/A N/A N/A
Virpax Pharmaceuticals N/A -1,554.34%-338.29%

Navidea Biopharmaceuticals has a beta of 1.75, indicating that its share price is 75% more volatile than the S&P 500. Comparatively, Virpax Pharmaceuticals has a beta of 1.58, indicating that its share price is 58% more volatile than the S&P 500.

Navidea Biopharmaceuticals has higher revenue and earnings than Virpax Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Navidea Biopharmaceuticals$8.13K2.46-$15.18MN/AN/A
Virpax PharmaceuticalsN/AN/A-$15.19MN/AN/A

In the previous week, Navidea Biopharmaceuticals' average media sentiment score of 0.00 equaled Virpax Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Navidea Biopharmaceuticals Neutral
Virpax Pharmaceuticals Neutral

Virpax Pharmaceuticals has a consensus target price of $75.00, indicating a potential upside of 19,180.21%. Given Virpax Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Virpax Pharmaceuticals is more favorable than Navidea Biopharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Navidea Biopharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Virpax Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

Navidea Biopharmaceuticals beats Virpax Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

Get Navidea Biopharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for NAVB and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NAVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NAVB vs. The Competition

MetricNavidea BiopharmaceuticalsDiagnostic substances IndustryMedical SectorNYSE Exchange
Market Cap$20K$17.11M$5.50B$20.64B
Dividend YieldN/AN/A5.38%3.74%
P/E RatioN/AN/A27.5528.09
Price / Sales2.4616.32389.8754.24
Price / CashN/AN/A36.6322.31
Price / BookN/A0.028.074.59
Net Income-$15.18M-$15.61M$3.17B$986.06M
7 Day PerformanceN/A-5.76%2.83%2.78%
1 Month PerformanceN/A3.81%3.70%5.41%
1 Year PerformanceN/A-35.48%35.41%14.62%

Navidea Biopharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NAVB
Navidea Biopharmaceuticals
N/A$0.00
flat
N/A-80.0%$20K$8.13K0.0010
VRPX
Virpax Pharmaceuticals
1.3976 of 5 stars
$0.32
+0.3%
$75.00
+23,634.2%
-97.1%$392KN/A0.007
KRBP
Kiromic BioPharma
N/AN/AN/AN/A$330KN/A-0.0660Gap Down
High Trading Volume
MYMD
MyMD Pharmaceuticals
N/A$0.13
+3.6%
N/A-93.6%$308KN/A0.006High Trading Volume
TCBP
TC Biopharm
N/A$0.68
-55.8%
$48.00
+6,948.5%
-99.5%$279K$4.76M0.0080High Trading Volume
CAPS
Capstone Therapeutics
N/A$1.80
+7.8%
N/AN/A$260K$44.88M0.0038Gap Up
High Trading Volume
VINC
Vincerx Pharma
2.6699 of 5 stars
$0.04
-12.0%
$40.00
+90,809.1%
-99.7%$230KN/A0.0060Gap Up
BON
Bon Natural Life
1.4291 of 5 stars
$1.25
-0.8%
N/AN/A$210K$23.84M0.00100
UPC
Universe Pharmaceuticals
N/A$3.75
+2.7%
N/A-99.8%$161K$23.02M0.00220
SMFL
Smart for Life
N/A$0.02
-62.0%
N/A-99.5%$108K$11.11M0.00110Gap Down
High Trading Volume
HSTO
Histogen
N/A$0.01
-43.5%
N/A-99.9%$43K$19K0.0020Gap Down

Related Companies and Tools


This page (NYSE:NAVB) was last updated on 7/4/2025 by MarketBeat.com Staff
From Our Partners